[Federal Register Volume 59, Number 203 (Friday, October 21, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-26141]
[[Page Unknown]]
[Federal Register: October 21, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 94N-0373]
Drug Export; Climara Estradiol Transdermal System 3.9
Milligram (mg) and 7.8 mg Patches
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that 3M
Pharmaceuticals has filed an application requesting approval for the
export of the human drug Climara estradiol transdermal system
3.9 mg and 7.8 mg patches to New Zealand.
ADDRESSES: Relevant information on this application may be directed to
the Dockets Management Branch (HFA-305), Food and Drug Administration,
rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact
person identified below. Any future inquiries concerning the export of
human drugs under the Drug Export Amendments Act of 1986 should also be
directed to the contact person.
FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug
Evaluation and Research (HFD-313), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-594-2073.
SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)
provide that FDA may approve applications for the export of drugs that
are not currently approved in the United States. Section 802(b)(3)(B)
of the act sets forth the requirements that must be met in an
application for approval. Section 802(b)(3)(C) of the act requires that
the agency review the application within 30 days of its filing to
determine whether the requirements of section 802(b)(3)(B) have been
satisfied. Section 802(b)(3)(A) of the act requires that the agency
publish a notice in the Federal Register within 10 days of the filing
of an application for export to facilitate public participation in its
review of the application. To meet this requirement, the agency is
providing notice that 3M Pharmaceuticals, 3M Center, Bldg. 270-3A-01,
St. Paul, MN 55144-1000, has filed an application requesting approval
for the export of the human drug Climara estradiol
transdermal system 3.9 mg and 7.8 mg patches to New Zealand.
Climara estradiol transdermal system 3.9 mg and 7.8 mg
patches is indicated in the treatment of moderate to severe vasomotor
symptoms associated with the menopause, treatment of vulval and vaginal
atrophy, treatment of hypoestrogenism due to hypogonadism, castration
or primary ovarian failure, and treatment of abnormal uterine bleeding
due to hormonal imbalance in the absence of organic pathology and only
when associated with a hypoplastic endometrium. The application was
received and filed in the Center for Drug Evaluation and Research on
August 15, 1994, which shall be considered the filing date for purposes
of the act.
Interested persons may submit relevant information on the
application to the Dockets Management Branch (address above) in two
copies (except that individuals may submit single copies) and
identified with the docket number found in brackets in the heading of
this document. These submissions may be seen in the Dockets Management
Branch between 9 a.m. and 4 p.m., Monday through Friday.
The agency encourages any person who submits relevant information
on the application to do so by October 31, 1994, and to provide an
additional copy of the submission directly to the contact person
identified above, to facilitate consideration of the information during
the 30-day review period.
This notice is issued under the Federal Food, Drug, and Cosmetic
Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the
Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the
Center for Drug Evaluation and Research (21 CFR 5.44).
Dated: September 29, 1994.
David B. Barr,
Deputy Director, Office of Compliance, Center For Drug Evaluation and
Research.
[FR Doc. 94-26141 Filed 10-20-94; 8:45 am]
BILLING CODE 4160-01-F
